Ifeanyichukwu Ifechidere: DOAC Interference in Coagulation Tests – Are You Spotting It?
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“That ‘positive’ lupus anticoagulant result… might not be real.
And if you don’t catch it, you could be part of a misdiagnosis.
Let me talk to you — the biomedical scientist reviewing that coag screen. You run a lupus anticoagulant panel.
dRVVT ratio? – Prolonged.
APTT-based test? – Also prolonged.
‘Positive for LA,’ right?
Not so fast.
Is the patient on a DOAC?
Because here’s what many don’t realise:
Direct oral anticoagulants (DOACs) — especially factor Xa inhibitors and direct thrombin inhibitors — can significantly interfere with phospholipid-dependent assays.
And the result? – False positives in lupus anticoagulant testing
I’ve seen it happen:
- Patients labelled as having antiphospholipid syndrome
- Unnecessary long-term anticoagulation decisions
- Clinical confusion…
All based on a misleading lab result
Here’s what should trigger your suspicion:
- Unexpected LA positivity with no clinical history
- Prolonged dRVVT and APTT in a patient on apixaban, rivaroxaban, or dabigatran
- Inconsistent confirmatory testing patterns
Because DOACs can:
- Prolong screening assays
- Affect confirmatory steps
- Mimic inhibitor patterns
And suddenly, your ‘LA positive’ isn’t a lupus anticoagulant at all…
It’s drug interference.
So before you validate that result, ask:
- ‘Do I know the anticoagulation status of this patient?’
- ‘Should this test have been performed while on a DOAC?’
- – ‘Do we need DOAC-neutralisation or alternative strategies?’
Because in coagulation…
Context isn’t optional — it’s everything.
This is the level of thinking that separates running tests from truly understanding them.
If you want to get better at spotting interferences, interpreting complex results, and protecting patients from misleading data…
I break it down with real case studies Simple, practical interpretation frameworks. No jargon. Just clarity. Because not every abnormal result is pathology. Sometimes… it’s the test being fooled.”

Other posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin